Additional file 1 of Palliative care interventions and outcome in patients with glioblastoma – a retrospective, single-center study
Lisa-Marie Lind(University Hospital Regensburg), Elisabeth Bumes(University Hospital Regensburg), M. Riemenschneider(University Hospital Regensburg), Anna Fischl(University Hospital Regensburg), Michael Rechenmacher(University Hospital Regensburg), Julia Maurer(University Hospital Regensburg), Oliver Koelbl(University Hospital Regensburg), Ulrich Kaiser(University of Applied Sciences Landshut), Tobias Pukrop(University Hospital Regensburg), P. Hau(University Hospital Regensburg), E Goettl(University Hospital Regensburg), Martin Proescholdt(University Hospital Regensburg), Ralf Linker(University Hospital Regensburg), Nils-Ole Schmidt, Wolfgang Herr(University Hospital Regensburg)
Cited by 0
Related Papers
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
|Cell Reports|2019|297